[The change of the anti-VEGF agent in the treatment of exceptionally active choroidal neovascular membrane in age-related macular degeneration].
Aim of this case report to present a case a male patient with age related macular degeneration succesfully treated by anti-VEGF substances different types. The autor presents a case of 83 year old male with active choroidal neovasculare membrane. In this patient, the best corrected visual acuity (BCVA) of the left eye was 4/10 and the central retina thickness of the left eye was 320 microm. Activity of neovascular membrane was verified by OCT and FAG. Treatment was started with anti-VEGF Macugen. After 2 intravitreal injections of Macugen was state of retina worse. Treatment of the left eye was terminated according to recommendation in Information about drug Macugen. After that was started intravitreal applications of Lucentis. The state of retina was stabilizated after four injections of Lucentis. BCVA of the left eye was 4/20 and the central retina thickness was 130 microm. It happend after one year from beginning of therapy.


CONCLUSIONS
Dosing of anti-VEGF substances results from clinical trials is suitable for treatment majority of patients with choroidal neovascular membrane. Change of anti-VEGF substance is necessary for stabilisation of state on retina in some cases.
Ocní oddelení Masarykovy nemocnice, Ustí nad Labem. martin.hovorka@mnul.cz
M
M
Hovorka
D000369:Aged, 80 and over; D000911:Antibodies, Monoclonal / Q000008:administration & dosage*; D061067:Antibodies, Monoclonal, Humanized; D052157:Aptamers, Nucleotide / Q000008:administration & dosage*; D020256:Choroidal Neovascularization / Q000150:complications / Q000188:drug therapy* / Q000473:pathology; D057915:Drug Substitution; D005451:Fluorescein Angiography; D006801:Humans; D058449:Intravitreal Injections; D008268:Macular Degeneration / Q000150:complications / Q000188:drug therapy* / Q000473:pathology; D008297:Male; D000069579:Ranibizumab; D041623:Tomography, Optical Coherence; D042442:Vascular Endothelial Growth Factors / Q000037:antagonists & inhibitors*
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D052157:Aptamers, Nucleotide; D042442:Vascular Endothelial Growth Factors; C495058:pegaptanib; D000069579:Ranibizumab